Treprostinil PatchPump - SteadyMed Therapeutics

Drug Profile

Treprostinil PatchPump - SteadyMed Therapeutics

Alternative Names: Trevyent

Latest Information Update: 22 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SteadyMed Therapeutics
  • Class Antihypertensives; Prostaglandins; Small molecules; Vasodilators
  • Mechanism of Action Epoprostenol receptor agonists; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary hypertension
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Pulmonary arterial hypertension
  • Clinical Phase Unknown Pulmonary hypertension

Most Recent Events

  • 15 May 2018 Cipher Pharmaceuticals acquires Treprostinil PatchPump from Correvio Pharma in Canada
  • 02 Apr 2018 Cardiome announces intention to submit MAA to EMA for Pulmonary hypertension in Europe shortly in 2018
  • 30 Mar 2018 SteadyMed receives patent allowance for the PatchPump drug delivery device in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top